XellSmart is expanding deeper into neurodegenerative disease. The company has secured its fourth joint clearance from the U.S. FDA and China’s NMPA for a Phase I/II registrational clinical trial.
The latest program targets Multiple System Atrophy – Parkinsonian Type (MSA-P) using an off-the-shelf, allogeneic, universal, iPSC-derived neuron progenitor cell therapy.
This milestone builds on three prior FDA–NMPA clearances for programs targeting:
- Parkinson’s disease (PD)
- Spinal cord injury (SCI)
- Amyotrophic lateral sclerosis (ALS)
Together, the approvals position XellSmart as one of the most active iPSC-for-CNS developers globally.
Understanding MSA-P: A Severe, Fatal Disorder
Multiple System Atrophy (MSA) is recognized by the World Health Organization as a rare and fatal neurodegenerative disease with significant unmet medical need.
The Parkinsonian subtype (MSA-P) presents with:
- Bradykinesia
- Rigidity
- Gait impairment
- Severe autonomic dysfunction
- Orthostatic hypotension
- Urinary incontinence
The disease is driven by abnormal α-synuclein aggregation in oligodendrocytes, leading to widespread neuronal dysfunction and rapid progression.
Median survival after diagnosis: 6–10 years.
There are currently no approved therapies worldwide that can slow or reverse disease progression.
Current Standard of Care Falls Short
MSA-P shares overlapping motor symptoms with Parkinson’s disease, and treatment often mirrors PD therapy:
- Levodopa/carbidopa
- Other dopaminergic agents
However:
- Clinical response is often limited
- Benefits are typically weaker than in PD
- Disease progression remains unchecked
Non-pharmacologic care focuses on:
- Autonomic symptom management
- Rehabilitation
- Fall prevention
- Nutritional support
None alter disease trajectory.
XellSmart’s Approach: Regenerative Strategy
XellSmart’s therapy employs:
- Allogeneic, universal iPSC-derived neuron progenitor cells
- Off-the-shelf design
- Subtype-specific neuronal targeting
The proposed mechanism aims to:
- Regenerate dopamine secretion
- Restore neural circuits
- Improve the brain microenvironment
The MSA-P trial is expected to initiate in China and the US in 2026.
A Broad CNS-Focused Pipeline
To date, XellSmart has secured nine IND clearances from the FDA and NMPA for Phase I/II registrational trials.
Programs target major CNS diseases:
- Parkinson’s disease
- Spinal cord injury
- ALS
- MSA-P
Key trials include:
- China Phase I/II and US Phase I trials in primary PD, led by Beijing Tiantan Hospital
- China’s first randomized, double-blind universal cell therapy trial in early-onset PD, led by Huashan Hospital Fudan University
- SCI trials led by The Third Affiliated Hospital of Sun Yat-sen University
- ALS trials led by Peking University Third Hospital
Notably, the ALS program received Orphan Drug Designation from the U.S. Food and Drug Administration in 2023.
Encouraging Early Data in Parkinson’s Disease
The MSA-P program builds on clinical observations from XellSmart’s PD registrational trials.
Among more than a dozen moderate-to-severe PD patients treated:
- No unexpected safety signals reported
- Positive trends in:
- ON/OFF state duration
- MDS-UPDRS motor scores
- Extended daily “ON” time by several hours
- Reduction in debilitating “OFF” periods
Brain PET imaging suggests:
- Survival of engrafted neurons
- Potential functional dopaminergic activity in the putamen
These signals support further investigation of iPSC-derived cell transplantation via stereotactic neurosurgery.
Backed by Capital and Infrastructure
Founded in 2021 by Dr. Xiang Li (Michael Lee), XellSmart has secured five consecutive years of financing from venture investors including:
- FreeS Fund
- Qiming Venture Partners
- LAV
- Sequoia Capital China (Hongshan)
- 3SBIO
Funding has supported:
- Advancement into pivotal clinical stages
- GMP-grade facility upgrades
- Large-scale standardized production
- Strengthened quality control systems
The company operates from a 5,000㎡ R&D center and B+A-grade GMP manufacturing facilities in Shanghai and Suzhou.
The Bigger Picture
Neurodegenerative diseases remain among the most underserved therapeutic areas. If XellSmart’s off-the-shelf iPSC-derived platform can demonstrate:
- Safety
- Functional neuronal integration
- Durable clinical benefit
It could represent a fundamental shift in how CNS disorders are treated.
With four consecutive FDA–NMPA clearances and nine IND approvals overall, XellSmart is moving aggressively into one of medicine’s most difficult frontiers.
